{"id":513,"date":"2025-03-17T09:56:18","date_gmt":"2025-03-17T09:56:18","guid":{"rendered":"https:\/\/rttrialsqa.org.uk\/?page_id=513"},"modified":"2025-03-17T09:56:18","modified_gmt":"2025-03-17T09:56:18","slug":"star-trap","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=513","title":{"rendered":"STAR-TRAP"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

STAR-TRAP: Phase II clinical trial of using stereotactic body radiotherapy (SBRT) on first line androgen receptor targeted therapy for metastatic prostate cancer<\/strong><\/h2>\n\n\n\n
Trial Summary:<\/strong><\/h5>\n\n\n\n

The STAR-TRAP trial is a Phase II multicentre randomised controlled study investigating whether stereotactic body radiotherapy (SBRT) improves outcomes when added to first-line androgen receptor pathway inhibitors for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Sponsored by the Institute of Cancer Research (ICR) and funded by Prostate Cancer UK, the trial includes two cohorts: the induced oligometastatic (iOM) group, consisting of patients whose poly-metastatic disease has been downstaged by systemic therapy, and the oligoprogressive (OP) group, comprising patients with limited disease progression on first-line therapy. The study evaluates whether consolidative SBRT alongside standard systemic treatment can enhance failure-free survival in the iOM cohort and delay treatment discontinuation in the OP cohort, while also assessing effects on overall survival, radiological progression-free survival, time to second progression, symptomatic skeletal events, and patient-reported outcomes. Imaging sub-studies using PSMA PET-CT and WBMRI aim to identify patients most likely to benefit. Patients will receive either systemic therapy alone or with SBRT to metastatic sites, following strict quality assurance protocols. Follow-up aligns with standard care to monitor treatment response, disease progression, and adverse effects. This trial could refine metastatic prostate cancer treatment, potentially establishing SBRT as a standard adjunct to systemic therapy.<\/p>\n\n\n\n

Prostate SABR QA Summary:<\/strong><\/h5>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>1 Case by all trial centres<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>1 prostate SBRT case, subject to streamlining.
\nNew benchmark only if centre has changed technique\/equipment since (please discuss process with RTTQA contact)<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>The outlining and planning for at least the first cohort of patients recruited by each trial centre will be subject to review<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Dosimetry Audit<\/td><\/td>\"\"<\/td>Subject to streamlining via audit from clinical trial QA groups and UK dosimetry audit network groups<\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>PACE-A\/B\/C, PACE-NODES, PEARLS, PIVOTALboost<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n
Oligomet SABR QA Summary:<\/strong><\/h5>\n\n\n\n

All QA activity will be streamlined with previous trial QA or SABR QA programmes, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td>2024 SABR QA Programme: FQ required<\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>All centres should already have \u22652 clinicians approved through streamlining or cascade training. Benchmark only if centre has <2 clinicians accredited (1 case per anatomical site)<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>All centres should already be credentialed through streamlining. Benchmark only if centre has changed technique\/equipment since (please discuss process with RTTQA contact)<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Prospective: At least the 1st Patient for each metastatic site<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Dosimetry Audit<\/td><\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>CtE, SEP, HALT, TRAP, SARON, STAR-TRAP, ATLANTA, SOPRANO<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA Contact:<\/strong> enh-tr.star-trapqa@nhs.net<\/a><\/p>\n\n\n\n

Chief Investigator:<\/strong> Dr Julia Murray<\/p>\n\n\n\n

Sponsor:<\/strong> Institute of Cancer Research (startrap-icrctsu@icr.ac.uk<\/a>)<\/p>\n\n\n\n

Funder: <\/strong>Prostate Cancer UK<\/p>\n\n\n\n

CTU Contact:<\/strong> ICR Clinical Trials and Statistics Unit (ICR-CTSU) (startrap-icrctsu@icr.ac.uk<\/a>)<\/p>\n","protected":false},"excerpt":{"rendered":"

STAR-TRAP: Phase II clinical trial of using stereotactic body radiotherapy (SBRT) on first line androgen receptor targeted therapy for metastatic prostate cancer […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-513","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=513"}],"version-history":[{"count":1,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/513\/revisions"}],"predecessor-version":[{"id":515,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/513\/revisions\/515"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}